Skip to content
- Which disease-modifying Alzheimer’s drugs are the most promising? The Guardian
- Surrey Alzheimer’s drug trial patient shares his experience of donanemab Surrey Live
- New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE NICE
- Pioneering Alzheimer’s drug rejected for widespread use in NHS in England Sky News
- Donanemab licensed for early stages of Alzheimer’s disease in adult patients who have one or no copies of apolipoprotein E4 gene GOV.UK